Biomarkers of Atrial Fibrillation in Metabolic Syndrome

Georgakopoulos, Christos; Vlachopoulos, Charalambos; Lazaros, Georgios; Tousoulis, Dimitrios

doi:10.2174/0929867324666171012105528

Cited by 15 publications

(16 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Абдоминальное ожирение и МС характеризуются дисбалансом адипокинов, в частности, гиперлептинемией и снижением концентрации протективного цитокина -адипонектина. Ранее было доказано, что лептин и адипонектин независимо ассоциированы с уровнем маркеров воспаления [13]. МС ассоциирован с повышенным уровнем провоспалительных цитокинов (ИЛ-6, ФНО-α), а также адипокинов (лептин, грелин), мо- чевой кислоты и снижением уровня противовоспалительных цитокинов (ИЛ-10) [24].…”

Section: Discussionunclassified

“…В свою очередь, провоспалительные цитокины индуцируют инсулинорезистентность. В частности, ИЛ-6 повышает резистентность к инсулину, ассоциирован с отдельными компонентами МС, а также высокие концентрации этого адипокина ассоциированы с тяжестью проявлений МС [12,13].…”

Section: Discussionunclassified

“…Ожирению и МС также свойственно субклиническое хроническое воспаление, при этих заболеваниях установлено повышение в крови циркулирующих маркеров воспаления, в т.ч. ИЛ-6, СРБ и ФНО-α [12,13].…”

Section: Biomarkers Of Inflammation Parameters Characterizing Obesitunclassified

“…ИЛ-6, ИЛ-1β и др.) [17], которые способны вызвать локальное воспаление и участвуют в формировании фиброза предсердий -субстрата для развития ФП [13,18]. Метаанализ, проведенный Antonopoulos AS и Antoniades С, свидетельствует о том, что большой объем ЭЖТ ассоциирован с развитием ФП [19].…”

Section: Biomarkers Of Inflammation Parameters Characterizing Obesitunclassified

See 3 more Smart Citations

Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome

et al. 2021

View full text Add to dashboard Cite

Aim. To determine the blood level of inflammatory markers, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation (AF) in combination with metabolic syndrome (MS).Material and methods. This single-stage case-control study included 677 subjects aged 35 to 65 years: patients with MS (n=407), of which 128 patients with AF; comparison group — patients with AF without MS (n=75); control group — practically healthy subjects without cardiovascular diseases and metabolic disorders (n=195).Results. It was found that the blood concentration of circulating pro-inflammatory biomarkers in patients with AF and MS is higher than in patients with AF without MS: C-reactive protein (CRP) (4,43 (2,68-4,98) and 2,33 (1,08-4,7) mg/L, p<0,0001), interleukin-6 (IL-6) (2,5 (1,28-5,13) and 1,27 (0,68-2,7) pg/ml, p<0,0001) and tumor necrosis factor-α (TNF-α) (5,18 (2,63-7,32) and 3,42 (2,115,48) pg/ml, p<0,0001). The serum CRP concentration positively correlates with left (ρ=0,451, p<0,0001) and right atrial (ρ=0,412, p<0,000) volumes, as well as with the waist circumference (ρ=0,503, p<0,001) and epicardial fat thickness (ρ=0,550, p<0,001). Plasma IL-6 and serum TNF-α levels correlated to a lesser extent with parameters characterizing atrial remodeling, but had a strong positive relationship with epicardial fat thickness. According to multivariate analysis, it was found that an increase in the epicardial fat thickness had a greater effect on an increase in blood concentration of CRP, IL-6 and TNF-α, in contrast to other parameters characterizing obesity, such as body mass index and waist circumference.Conclusion. An increase in the blood concentration of proinflammatory biomarkers CRP, IL-6, and TNF-α is associated with cardiac remodeling and epicardial fat thickness in patients with MS and probably has a pathogenetic role in increasing the AF risk in this cohort of patients.

show abstract

Section: Discussionunclassified

Section: Biomarkers Of Inflammation Parameters Characterizing Obesitunclassified

See 2 more Smart Citations

Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome

et al. 2021

View full text Add to dashboard Cite

show abstract

“…В ряде работ установлено, что МС способствует развитию различных нарушений ритма и проводимости [55,56]. Показано, что существует взаимосвязь между НАЖБП и фибрилляцией предсердий (ФП).…”

unclassified

Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease

Саликова

Ivanyuk

2020

jour

View full text Add to dashboard Cite

In recent years, non-alcoholic fatty liver disease (NAFLD) has been associated with metabolic syndrome (MetS) and is considered as one of its components. The mortality rate of patients with NAFLD is due not so much to the progression of liver damage as to cardiovascular complications. This review summarizes current data on possible pathophysiological mechanisms linking NAFLD and cardiovascular diseases. The article analyzes the clinical eﬀects of NAFLD on the heart and blood vessels: atherosclerosis, myocardial remodeling, rhythm and conduction disorders, and chronic heart failure.

show abstract

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Berezin

2020

Diabetes Ther

View full text Add to dashboard Cite

The aim of this narrative review is to update the current knowledge on the differential choice of circulating cardiac biomarkers in patients with prediabetes and established type 2 diabetes mellitus (T2DM). There are numerous circulating biomarkers with unconfirmed abilities to predict clinical outcomes in pre-DM and DM individuals; the prognostication ability of the cardiac biomarkers reported here has been established, and they are still being studied. The conventional cardiac biomarkers, such as natriuretic peptides (NPs), soluble suppressor tumorigenisity-2, high-sensitivity circulating cardiac troponins and galectin-3, were useful to ascertain cardiovascular (CV) risk. Each cardiac biomarker has its strengths and weaknesses that affect the price of usage, specificity, sensitivity, predictive value and superiority in face-to-face comparisons. Additionally, there have been confusing reports regarding their abilities to be predictably relevant among patients without known CV disease. The large spectrum of promising cardiac biomarkers (growth/differential factor-15, heart-type fatty acid-binding protein, cardiotrophin-1, carboxy-terminal telopeptide of collagen type 1, apelin and noncoding RNAs) is discussed in the context of predicting CV diseases and events in patients with known prediabetes and T2DM. Various reasons have been critically discussed related to the variable findings regarding biomarker-based prediction of CV risk among patients with metabolic disease. It was found that NPs and hs-cTnT are still the most important tools that have an affordable price as well as high sensitivity and specificity to predict clinical outcomes among patients with pre-DM and DM in routine clinical practice, but other circulating biomarkers need to be carefully investigated in large trials in the future.

show abstract

Biomarkers of Atrial Fibrillation in Metabolic Syndrome

Cited by 15 publications

References 114 publications

Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome

Biomarkers of inflammation, parameters characterizing obesity and cardiac remodeling in patients with atrial fibrillation and metabolic syndrome

Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Contact Info

Product

Resources

About